23 results
8-K
EX-99.2
VSTM
Verastem Inc
24 May 24
Plan to complete NDA submission with the mature RAMP 201 dataset, anticipated to include 12 months of follow-up, in the second half of 2024
7:01am
market preparation activities Engaged with 1/3 of prevalent patient population 2 & ongoing engagement with HCPs 3 Excitement for avutometinib … to support patients and physicians navigating payer barriers Ongoing engagement with plans for rapid uptake Support of community practices through
8-K
EX-1.1
VSTM
Verastem Inc
21 Jun 23
Other Events
7:00am
of the Company, any of its Subsidiaries or their respective stockholders, creditors, employees or any other party and (c) the Company’s engagement
8-K
EX-10.1
nu6dz6jix a14k
28 Feb 20
Verastem Oncology Announces $100 Million Private Placement Offering of Common Stock to Premier Life Sciences Investors
6:13am
8-K
EX-99.1
tb2twoj6
13 Jan 20
Entry into a Material Definitive Agreement
6:03am
8-K
EX-99.1
6lno8vqs4vmd
17 Oct 18
Other Events
8:02am
424B5
cjp v2u13b1btprdb
12 Oct 18
Prospectus supplement for primary offering
5:24pm
424B5
f4eqr1b b6
11 Oct 18
Prospectus supplement for primary offering
4:55pm